Featured projects

Patient-derived liver biopsy-organoids for personalized medicine in NAFLD (Non-Alcoholic Fatty Liver Disease): towards real time assessment of drug response (B-ORG)

Principal investigator: Pau Sancho Bru.
Funder: Ministerio de Ciencia e Innovación .

Code: IBEC_ProyectCompl22.

Duration: 13/04/2023 - 31/12/2024
Dissecting the role of the 14q32 region in hepatoblastoma Hblast14

Principal investigator: Pau Sancho Bru.
Funder: Worldwide Cancer Research .

Code: INT_WWCR_22.

Duration: 01/04/2023 - 31/03/2026
Off the shelf hepatic stellate cells for liver disease modeling and drug screening

Principal investigator: Pau Sancho Bru.
Funder: Instituto de Salud Carlos III .

Code: FIS_DTS22.

Duration: 01/01/2023 - 31/12/2025
Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH transition to inform early prevention and treatment strategies. (Halt-RONIN)

Principal investigator: Pau Sancho Bru.
Funder: European Commission .

Duration: 01/12/2022 - 30/11/2026
Mechanisms of impaired liver regeneration in alcoholic liver disease: drivers and therapeutic targets

Principal investigator: Pau Sancho Bru.
Funder: Instituto de Salud Carlos III .

Code: PI20/00765.

Duration: 01/01/2021 - 31/12/2023
Understanding hepatoblastoma to design new personalized treatments (HB-Project)

Principal investigator: Pau Sancho Bru.
Funder: Asociación Española Contra el Cáncer (AECC). .

Code: AECC-Proyectos19.

Duration: 01/12/2019 - 30/11/2022
Liver-enriched Transcription Factors as Prognostic Markers and Therapeutic Targets in Alcoholic Hepatitis (LiverTF)

Principal investigator: Pau Sancho Bru.
Funder: National Institutes of Health (NIH) .

Code: 5U01AA026972.

Duration: 22/09/2018 - 30/06/2020

The research of this group can be carried out thanks to the funders.

Featured projects

Patient-derived liver biopsy-organoids for personalized medicine in NAFLD (Non-Alcoholic Fatty Liver Disease): towards real time assessment of drug response (B-ORG)

Dissecting the role of the 14q32 region in hepatoblastoma Hblast14

Off the shelf hepatic stellate cells for liver disease modeling and drug screening

Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH transition to inform early prevention and treatment strategies. (Halt-RONIN)

Mechanisms of impaired liver regeneration in alcoholic liver disease: drivers and therapeutic targets

Understanding hepatoblastoma to design new personalized treatments (HB-Project)

Liver-enriched Transcription Factors as Prognostic Markers and Therapeutic Targets in Alcoholic Hepatitis (LiverTF)

Major founders